ANDOVER, Mass.--\Today, Formatech has selected the next candidate for its Fillanthropy Program:
ViroMed's VM206 therapeutic cancer vaccine. Under the Fillanthropy Program, Formatech will donate the services required to aseptically fill and finish one lot of the vaccine to support ViroMed's upcoming clinical trials. Formatech plans to complete the production run in March 2010.

"We're excited to have the opportunity to work with ViroMed on this program," said Jeffrey Bernard, Formatech's Director of Business Development. "VM206 is a plasmid DNA vaccine that targets HER2/neu positive breast cancer. Animal studies have demonstrated the vaccine's ability to eliminate tumors and to prevent relapse and metastases. We are hopeful and optimistic that VM206 will prove to be effective in human trials."

"We would like to thank Formatech and the Fillanthropy Program for choosing to support ViroMed's development of VM206," said Dr. Sunyoung Kim, Co-CEO of ViroMed. "We believe that our goal to develop medicines for diseases for which there are no current effective treatments is in line with the program's mission of helping to make new drugs available as soon as possible."

To obtain more information on participating in the Fillanthropy Program, companies are encouraged to contact Jeffrey Bernard, Director of Business Development at Formatech (jbernard@formatech.com).

About the Fillanthropy Program
Each month beginning in January 2010, Formatech will donate the services required to aseptically fill and finish one lot of drug product for selected therapeutic candidates that are entering human clinical trials. To be eligible, companies must be developing a clinical candidate that is delivered as a sterile injectable product. When selecting a candidate, Formatech considers both the product's potential therapeutic benefit and the financial need of the sponsor. To apply for participation in this program, companies are encouraged to contact Jeffrey Bernard at 978-725-9077 x 3164 or jbernard@formatech.com.

About Formatech

Formatech, founded in 1993, is a contract development and manufacturing organization based in Andover, Massachusetts. The company provides unique solutions to product development and manufacturing challenges, including: preformulation/formulation development of all common dosage forms, such as lyophilized dosage forms; cell culture/fermentation process development and purification/downstream process optimization. Their aseptic manufacturing facility produces liquid and lyophilized dosage units for clinical supplies or small-scale commercial products.

Manufacturing support services include compounding/formulation, diafiltration/concentration (UF/DF), release testing, and full ICH Guideline Stability Programs. Formatech's mission is to "Help make new drugs happen at the speed of science."

About ViroMed Co., Ltd.
ViroMed Co., Ltd. is a biopharmaceutical development company located in Seoul, Korea, focusing on novel DNA and protein-based therapeutics, botanical drugs, and nutraceuticals for various diseases. ViroMed now has five products in development targeting cardiovascular disease, cancer, and immune-related disorders. To learn more about the company and its products, visit www.viromed21.com.

About VM206
VM206 is a therapeutic cancer vaccine targeting HER2/neu positive breast cancer. HER2/neu is over-expressed in about 30% of breast cancers and is strongly associated with poor prognosis. VM206 can elicit both humoral and cellular immune responses to HER2/neu, resulting in a reduction in the growth of breast cancer, as well as the recurrence rate.